 Nancy Madinger
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trench Fever | 1 | 2022 | 3 | 0.830 |
Why?
| | Bartonella quintana | 1 | 2022 | 3 | 0.830 |
Why?
| | Endocarditis | 1 | 2022 | 32 | 0.790 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 140 | 0.690 |
Why?
| | Trichuriasis | 1 | 2016 | 4 | 0.530 |
Why?
| | Strongyloidiasis | 1 | 2016 | 4 | 0.530 |
Why?
| | Pregnancy Complications, Parasitic | 1 | 2016 | 9 | 0.530 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2016 | 16 | 0.530 |
Why?
| | Diphyllobothriasis | 1 | 2015 | 2 | 0.510 |
Why?
| | Diphyllobothrium | 1 | 2015 | 2 | 0.510 |
Why?
| | Sexual Behavior | 1 | 2019 | 434 | 0.480 |
Why?
| | Anemia | 1 | 2016 | 143 | 0.480 |
Why?
| | Program Evaluation | 1 | 2019 | 820 | 0.470 |
Why?
| | Carbapenems | 1 | 2014 | 16 | 0.460 |
Why?
| | Klebsiella Infections | 1 | 2014 | 23 | 0.450 |
Why?
| | beta-Lactamases | 1 | 2014 | 25 | 0.450 |
Why?
| | Klebsiella pneumoniae | 1 | 2014 | 41 | 0.450 |
Why?
| | Curriculum | 1 | 2019 | 813 | 0.420 |
Why?
| | Rectum | 1 | 2014 | 151 | 0.420 |
Why?
| | Disease Outbreaks | 1 | 2014 | 307 | 0.370 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2021 | 61 | 0.340 |
Why?
| | Anti-Bacterial Agents | 6 | 2021 | 1472 | 0.340 |
Why?
| | Internship and Residency | 1 | 2019 | 920 | 0.340 |
Why?
| | Methicillin | 1 | 2009 | 11 | 0.320 |
Why?
| | HIV Infections | 2 | 2022 | 2453 | 0.310 |
Why?
| | Platelet Transfusion | 1 | 2009 | 55 | 0.300 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2022 | 179 | 0.300 |
Why?
| | Drug Resistance, Bacterial | 3 | 2017 | 156 | 0.260 |
Why?
| | Enterobacteriaceae | 2 | 2021 | 33 | 0.260 |
Why?
| | Blood Platelets | 1 | 2009 | 326 | 0.260 |
Why?
| | Immunoglobulin G | 2 | 2022 | 766 | 0.250 |
Why?
| | Rhizopus | 1 | 2005 | 5 | 0.250 |
Why?
| | Facial Pain | 1 | 2005 | 11 | 0.240 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 385 | 0.240 |
Why?
| | Mucormycosis | 1 | 2005 | 20 | 0.240 |
Why?
| | Chaetomium | 1 | 2003 | 3 | 0.220 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 377 | 0.220 |
Why?
| | Mycoses | 1 | 2003 | 66 | 0.210 |
Why?
| | Sinusitis | 1 | 2005 | 174 | 0.210 |
Why?
| | Brain Diseases | 1 | 2003 | 124 | 0.200 |
Why?
| | Peptide Nucleic Acids | 1 | 2021 | 3 | 0.190 |
Why?
| | Enterobacteriaceae Infections | 1 | 2021 | 33 | 0.180 |
Why?
| | Cross Infection | 2 | 2009 | 194 | 0.180 |
Why?
| | Oligonucleotides, Antisense | 1 | 2021 | 100 | 0.180 |
Why?
| | Bacteria | 2 | 2017 | 725 | 0.180 |
Why?
| | Pericarditis | 1 | 2020 | 9 | 0.180 |
Why?
| | Cryptococcus neoformans | 1 | 2020 | 18 | 0.170 |
Why?
| | Cryptococcosis | 1 | 2020 | 23 | 0.170 |
Why?
| | Drug Design | 1 | 2021 | 147 | 0.170 |
Why?
| | Microbial Sensitivity Tests | 5 | 2021 | 300 | 0.170 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2005 | 519 | 0.170 |
Why?
| | Female | 14 | 2022 | 59349 | 0.160 |
Why?
| | Humans | 24 | 2022 | 114080 | 0.150 |
Why?
| | Antifungal Agents | 3 | 2020 | 128 | 0.150 |
Why?
| | Adult | 10 | 2020 | 30395 | 0.150 |
Why?
| | Computational Biology | 1 | 2021 | 528 | 0.140 |
Why?
| | Middle Aged | 8 | 2022 | 26621 | 0.140 |
Why?
| | Superoxides | 1 | 2017 | 190 | 0.140 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2009 | 192 | 0.140 |
Why?
| | Mebendazole | 1 | 2016 | 2 | 0.130 |
Why?
| | Strongyloides | 1 | 2016 | 2 | 0.130 |
Why?
| | Trichuris | 1 | 2016 | 3 | 0.130 |
Why?
| | Albendazole | 1 | 2016 | 4 | 0.130 |
Why?
| | Ivermectin | 1 | 2016 | 9 | 0.130 |
Why?
| | Feces | 2 | 2015 | 372 | 0.130 |
Why?
| | Xanthomonas | 1 | 1996 | 2 | 0.130 |
Why?
| | Male | 12 | 2022 | 55420 | 0.130 |
Why?
| | Hematocrit | 1 | 2016 | 86 | 0.130 |
Why?
| | Acinetobacter | 1 | 1996 | 13 | 0.130 |
Why?
| | Pseudomonas | 1 | 1996 | 26 | 0.130 |
Why?
| | Praziquantel | 1 | 2015 | 5 | 0.130 |
Why?
| | Anthelmintics | 1 | 2015 | 8 | 0.130 |
Why?
| | Quantum Dots | 1 | 2016 | 34 | 0.130 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 1996 | 36 | 0.130 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 663 | 0.130 |
Why?
| | Migraine Disorders | 1 | 2016 | 82 | 0.120 |
Why?
| | Staphylococcal Infections | 2 | 2009 | 340 | 0.120 |
Why?
| | o-Phthalaldehyde | 1 | 2014 | 3 | 0.120 |
Why?
| | Glutaral | 1 | 2014 | 14 | 0.120 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1994 | 25 | 0.110 |
Why?
| | Heart Transplantation | 1 | 2020 | 670 | 0.110 |
Why?
| | Disinfectants | 1 | 2014 | 34 | 0.110 |
Why?
| | Bacterial Infections | 2 | 2011 | 217 | 0.110 |
Why?
| | Hemoglobins | 1 | 2016 | 308 | 0.110 |
Why?
| | Administration, Oral | 1 | 2016 | 725 | 0.110 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 102 | 0.110 |
Why?
| | Confidence Intervals | 1 | 2014 | 302 | 0.110 |
Why?
| | Bacteria, Anaerobic | 1 | 1993 | 20 | 0.110 |
Why?
| | Genital Diseases, Female | 1 | 1993 | 25 | 0.110 |
Why?
| | Intestines | 1 | 2016 | 325 | 0.100 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2014 | 200 | 0.100 |
Why?
| | Population Surveillance | 1 | 2014 | 385 | 0.090 |
Why?
| | Young Adult | 3 | 2015 | 10459 | 0.090 |
Why?
| | Azithromycin | 1 | 2011 | 80 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1422 | 0.090 |
Why?
| | Intensive Care Units | 1 | 2014 | 614 | 0.080 |
Why?
| | Technology Assessment, Biomedical | 1 | 1989 | 29 | 0.080 |
Why?
| | Daptomycin | 1 | 2009 | 18 | 0.080 |
Why?
| | Pregnancy | 3 | 2016 | 5503 | 0.080 |
Why?
| | Bacterial Proteins | 1 | 1994 | 735 | 0.080 |
Why?
| | Animals | 4 | 2021 | 31570 | 0.080 |
Why?
| | Vancomycin | 1 | 2009 | 75 | 0.080 |
Why?
| | Th1 Cells | 1 | 2009 | 123 | 0.070 |
Why?
| | Aged | 5 | 2020 | 18973 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 1989 | 337 | 0.070 |
Why?
| | Bacteremia | 1 | 2009 | 160 | 0.070 |
Why?
| | Dendritic Cells | 1 | 2009 | 435 | 0.060 |
Why?
| | Cytosine | 1 | 2005 | 43 | 0.060 |
Why?
| | Amphotericin B | 1 | 2005 | 28 | 0.060 |
Why?
| | Pregnancy Complications | 1 | 1989 | 430 | 0.060 |
Why?
| | Organophosphonates | 1 | 2005 | 89 | 0.060 |
Why?
| | Herpes Simplex | 1 | 2005 | 87 | 0.060 |
Why?
| | Drug Resistance, Microbial | 2 | 1996 | 66 | 0.060 |
Why?
| | Colorado | 1 | 2014 | 4092 | 0.060 |
Why?
| | Pneumonia | 1 | 1989 | 563 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2020 | 9051 | 0.060 |
Why?
| | Intestinal Mucosa | 1 | 2009 | 532 | 0.060 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 907 | 0.060 |
Why?
| | Liposomes | 1 | 2005 | 146 | 0.060 |
Why?
| | Autopsy | 1 | 2003 | 83 | 0.050 |
Why?
| | Oxidation-Reduction | 2 | 2017 | 917 | 0.050 |
Why?
| | Hodgkin Disease | 1 | 2005 | 121 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2009 | 960 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 281 | 0.050 |
Why?
| | Cholangitis | 1 | 2002 | 19 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2021 | 47 | 0.050 |
Why?
| | RAW 264.7 Cells | 1 | 2021 | 41 | 0.050 |
Why?
| | 3T3 Cells | 1 | 2021 | 140 | 0.050 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2002 | 91 | 0.040 |
Why?
| | Pseudomonas Infections | 1 | 2002 | 184 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 9 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 169 | 0.040 |
Why?
| | Microbial Viability | 1 | 2021 | 79 | 0.040 |
Why?
| | Fluconazole | 1 | 2020 | 16 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 180 | 0.040 |
Why?
| | Fetal Blood | 1 | 2002 | 268 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2005 | 642 | 0.040 |
Why?
| | HeLa Cells | 1 | 2021 | 563 | 0.040 |
Why?
| | Immunocompromised Host | 1 | 2020 | 192 | 0.040 |
Why?
| | Organ Transplantation | 1 | 2020 | 159 | 0.040 |
Why?
| | Echocardiography | 1 | 2020 | 569 | 0.040 |
Why?
| | Medication Adherence | 1 | 2022 | 531 | 0.030 |
Why?
| | Cytotoxins | 1 | 1994 | 17 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 2017 | 268 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2022 | 12521 | 0.030 |
Why?
| | Nanoparticles | 1 | 2017 | 312 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 1994 | 103 | 0.030 |
Why?
| | Gram-Negative Anaerobic Bacteria | 1 | 1993 | 1 | 0.030 |
Why?
| | Gram-Positive Bacteria | 1 | 1993 | 45 | 0.030 |
Why?
| | Cystic Fibrosis | 1 | 2002 | 955 | 0.030 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1992 | 115 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1993 | 1003 | 0.020 |
Why?
| | Nasopharynx | 1 | 2011 | 61 | 0.020 |
Why?
| | Adolescent | 3 | 2022 | 17811 | 0.020 |
Why?
| | Macrolides | 1 | 2011 | 57 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 1992 | 127 | 0.020 |
Why?
| | Hospital Bed Capacity, 500 and over | 1 | 1989 | 3 | 0.020 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2009 | 17 | 0.020 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2014 | 328 | 0.020 |
Why?
| | Obstetric Labor, Premature | 1 | 1989 | 33 | 0.020 |
Why?
| | New York City | 1 | 1989 | 70 | 0.020 |
Why?
| | Infant Mortality | 1 | 1989 | 91 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 62 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 52 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 159 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 312 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2009 | 413 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 139 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 219 | 0.020 |
Why?
| | Risk Factors | 2 | 2009 | 8612 | 0.020 |
Why?
| | United States | 2 | 2014 | 12144 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2009 | 719 | 0.020 |
Why?
| | Simplexvirus | 1 | 2005 | 80 | 0.020 |
Why?
| | Mice | 1 | 2021 | 14847 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2009 | 1036 | 0.010 |
Why?
| | Length of Stay | 1 | 1989 | 957 | 0.010 |
Why?
| | Drug Resistance, Viral | 1 | 2005 | 99 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 237 | 0.010 |
Why?
| | Bile Duct Diseases | 1 | 2002 | 15 | 0.010 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2002 | 48 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2173 | 0.010 |
Why?
| | Antigens, CD34 | 1 | 2002 | 88 | 0.010 |
Why?
| | Drainage | 1 | 2002 | 145 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 2002 | 207 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 3862 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2002 | 292 | 0.010 |
Why?
| | Treatment Failure | 1 | 2002 | 330 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 6198 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2002 | 136 | 0.010 |
Why?
| | Graft Survival | 1 | 2002 | 443 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2002 | 341 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 4885 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 735 | 0.010 |
Why?
| | Neutrophils | 1 | 2002 | 1089 | 0.010 |
Why?
| | Chronic Disease | 1 | 2002 | 1579 | 0.010 |
Why?
| | Lung Diseases | 1 | 2002 | 690 | 0.010 |
Why?
| | Suppuration | 1 | 1992 | 8 | 0.010 |
Why?
| | Catalase | 1 | 1992 | 118 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 1846 | 0.010 |
Why?
| | Infant | 1 | 2002 | 7946 | 0.000 |
Why?
| | Child, Preschool | 1 | 2002 | 9121 | 0.000 |
Why?
| | Child | 1 | 2002 | 18408 | 0.000 |
Why?
|
|
Madinger's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|